Regulatory approval
Published by the Health Canada.
Health Canada approved midostaurin in combination with cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).
This is written in the approval document as:
RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | FLT3-ITD | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| Sensitivity (+) | FLT3 p.D835Y | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| Sensitivity (+) | FLT3 p.D835A | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| Sensitivity (+) | FLT3 p.D835E | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| Sensitivity (+) | FLT3 p.D835H | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| Sensitivity (+) | FLT3 p.D835N | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| Sensitivity (+) | FLT3 p.D835S | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| Sensitivity (+) | FLT3 p.D835V | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin | |
| Sensitivity (+) | FLT3 p.I836del | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Midostaurin |